69 related articles for article (PubMed ID: 6639104)
21. Overexpression of copper/zinc superoxide dismutase: a novel cause of murine muscular dystrophy.
Rando TA; Crowley RS; Carlson EJ; Epstein CJ; Mohapatra PK
Ann Neurol; 1998 Sep; 44(3):381-6. PubMed ID: 9749606
[TBL] [Abstract][Full Text] [Related]
22. Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle.
Gosselin LE; Williams JE
Muscle Nerve; 2006 Jun; 33(6):820-3. PubMed ID: 16502423
[TBL] [Abstract][Full Text] [Related]
23. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.
Schorlemmer HU; Bosslet K; Sedlacek HH
Cancer Res; 1983 Sep; 43(9):4148-53. PubMed ID: 6871856
[TBL] [Abstract][Full Text] [Related]
24. Long-term administration of pirfenidone improves cardiac function in mdx mice.
Van Erp C; Irwin NG; Hoey AJ
Muscle Nerve; 2006 Sep; 34(3):327-34. PubMed ID: 16770778
[TBL] [Abstract][Full Text] [Related]
25. First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant.
Burdi R; Didonna MP; Pignol B; Nico B; Mangieri D; Rolland JF; Camerino C; Zallone A; Ferro P; Andreetta F; Confalonieri P; De Luca A
Neuromuscul Disord; 2006 Apr; 16(4):237-48. PubMed ID: 16542837
[TBL] [Abstract][Full Text] [Related]
26. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
Mitrpant C; Fletcher S; Iversen PL; Wilton SD
J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
[TBL] [Abstract][Full Text] [Related]
27. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle.
Dunant P; Walter MC; Karpati G; Lochmüller H
Muscle Nerve; 2003 May; 27(5):624-7. PubMed ID: 12707984
[TBL] [Abstract][Full Text] [Related]
28. Effects of prednisone in canine muscular dystrophy.
Liu JM; Okamura CS; Bogan DJ; Bogan JR; Childers MK; Kornegay JN
Muscle Nerve; 2004 Dec; 30(6):767-73. PubMed ID: 15468337
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16-BL6 melanoma cells orthotopically implanted into syngeneic mice.
Aozuka Y; Koizumi K; Saitoh Y; Ueda Y; Sakurai H; Saiki I
Cancer Lett; 2004 Dec; 216(1):35-42. PubMed ID: 15500947
[TBL] [Abstract][Full Text] [Related]
30. Drugs in muscular dystrophy of the chicken: corticosterone-21-acetate.
Entrikin RK; Patterson GT; Wilson BW
Muscle Nerve; 1984 Feb; 7(2):130-6. PubMed ID: 6717489
[TBL] [Abstract][Full Text] [Related]
31. [Recovery from cyclophosphamide-induced myelosuppression accelerated by bestatin].
Uchida K; Kohi F; Yorimitsu S; Takahashi I; Kitajima K; Kimura I
Gan To Kagaku Ryoho; 1982 Feb; 9(2):220-4. PubMed ID: 7184398
[TBL] [Abstract][Full Text] [Related]
32. Progressive nuclear factor-kappaB activation resistant to inhibition by contraction and curcumin in mdx mice.
Durham WJ; Arbogast S; Gerken E; Li YP; Reid MB
Muscle Nerve; 2006 Sep; 34(3):298-303. PubMed ID: 16718687
[TBL] [Abstract][Full Text] [Related]
33. Strength and endurance in the therapeutic evaluation of prednisolone-treated MDX mice.
Hudecki MS; Pollina CM; Granchelli JA; Daly MK; Byrnes T; Wang JC; Hsiao JC
Res Commun Chem Pathol Pharmacol; 1993 Jan; 79(1):45-60. PubMed ID: 8434132
[TBL] [Abstract][Full Text] [Related]
34. Treatment of muscular dystrophy.
Bradley WG; Polgar JG; Williams MH; Boddie HG
Br Med J; 1972 Sep; 3(5828):699-700. PubMed ID: 4650857
[No Abstract] [Full Text] [Related]
35. [Duchenne Boulogne myopathy and free radicals; potential value of lazaroids in the treatment of this disease].
Poindron P; Metzinger L; Warter JM
C R Seances Soc Biol Fil; 1995; 189(6):1199-217. PubMed ID: 8763042
[No Abstract] [Full Text] [Related]
36. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy.
Bia BL; Cassidy PJ; Young ME; Rafael JA; Leighton B; Davies KE; Radda GK; Clarke K
J Mol Cell Cardiol; 1999 Oct; 31(10):1857-62. PubMed ID: 10525423
[TBL] [Abstract][Full Text] [Related]
37. Calpain translocation during muscle fiber necrosis and regeneration in dystrophin-deficient mice.
Spencer MJ; Tidball JG
Exp Cell Res; 1996 Aug; 226(2):264-72. PubMed ID: 8806430
[TBL] [Abstract][Full Text] [Related]
38. Correction of genetic disease by making sense from nonsense.
Kaufman RJ
J Clin Invest; 1999 Aug; 104(4):367-8. PubMed ID: 10449426
[No Abstract] [Full Text] [Related]
39. Glucagon treatment for muscular dystrophy in the mouse.
Pope RS
Am J Physiol; 1973 Sep; 225(3):518-20. PubMed ID: 4726484
[No Abstract] [Full Text] [Related]
40. Glucagon treatment of muscular dystrophic mice: a lack of effect.
Yen TT; Allan JA
Experientia; 1974 Aug; 30(8):908. PubMed ID: 4413580
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
